Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 02, 2017 09:00 ET | Source: Flexion Therapeutics

Flexion Therapeutics to Report Year-End 2016 Financial Results on March 9, 2017

BURLINGTON, Mass., March 02, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will host a conference call and webcast to provide an update on business...
February 23, 2017 07:30 ET | Source: Flexion Therapeutics

Flexion Therapeutics Initiates Clinical Trial to Evaluate the Safety of Repeat Administration of Zilretta™ (FX006) in Patients with Osteoarthritis of the Knee

BURLINGTON, Mass., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported it has enrolled the first patient in a clinical trial to evaluate the safety of repeat...
February 15, 2017 09:00 ET | Source: Flexion Therapeutics

Flexion Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference

BURLINGTON, Mass., Feb. 15, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will participate in...
February 07, 2017 07:30 ET | Source: Flexion Therapeutics

Flexion Therapeutics Announces New Drug Application for Zilretta™ (FX006) Accepted by U.S. Food and Drug Administration

FDA Reviewing Zilretta as Potential New Treatment for Osteoarthritis of the Knee Assigns PDUFA date of October 6, 2017 BURLINGTON, Mass., Feb. 07, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics,...
December 12, 2016 07:00 ET | Source: Flexion Therapeutics

Flexion Therapeutics Submits New Drug Application for Zilretta™ to Treat Knee Osteoarthritis Pain

BURLINGTON, Mass., Dec. 12, 2016 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced it has submitted a new drug application (NDA) to the U.S. Food and Drug Administration...
December 09, 2016 09:00 ET | Source: Flexion Therapeutics

Flexion Therapeutics to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference

BURLINGTON, Mass., Dec. 09, 2016 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will provide a...
November 16, 2016 09:00 ET | Source: Flexion Therapeutics

Flexion Therapeutics Announces Pricing of Public Offering of Common Stock

BURLINGTON, Mass., Nov. 16, 2016 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the pricing of an underwritten public offering of 3,600,000 shares of its common stock...
November 15, 2016 16:01 ET | Source: Flexion Therapeutics

Flexion Therapeutics Announces Proposed Public Offering of Common Stock

BURLINGTON, Mass., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it has commenced an underwritten public offering, subject to market and other...
November 11, 2016 09:00 ET | Source: Flexion Therapeutics

Flexion Therapeutics Announces Presentation of Phase 3 Data Demonstrating that Extended-Release Zilretta™ Achieves Clinically Significant Improvement of Pain, Stiffness and Function in Patients with Osteoarthritis of the Knee

DALLAS, Nov. 11, 2016 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that its lead investigational product candidate Zilretta (also known as FX006) demonstrated...
November 07, 2016 16:01 ET | Source: Flexion Therapeutics

Flexion Therapeutics Reports Third Quarter 2016 Financial Results

Successfully completed the transfer of the Zilretta™ manufacturing technology to Patheon - on track for NDA submission in December Met primary endpoint in clinical trial evaluating Zilretta in Type...